Conversion From Unresectable To Resectable Metastatic Colorectal Cancer.
About this study
Most patients with mCRC are treated with palliative chemotherapy and only a small number of patients with limited metastatic disease achieve long-term remission following metastasectomy. There is a growing need for more effective treatment in patients with liver-only mCRC to improve the rate of curative resection without compromising QOL.The current study is informed by our patient's needs. It aims to evaluate the rate of conversion therapy in patients with unresectable liver-only mCRC using the combination of FOLFOXIRI and bevacizumab and to assess the association between an early FDG-PT/CT response and other clinical and pathological biomarkers and hepatic metastasectomy.
- Condition
- Metastatic Colorectal Cancer
- Tested
- FOLFOXIRI and Bevacizumab
- Sponsor
- University of Saskatchewan
Who can join
- Age
- 18 to 70 years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 7
- Minimum age: 18 years
- Maximum age: 70 years
- Study condition: Metastatic Colorectal Cancer
- Adult patients, aged between 18 and 70 years with histologically proven adenocarcinoma or poorly differentiated carcinoma of the colon and rectum with unresectable liver-only metastases and no extra-hepatic disease.
- World Health Organization (WHO) performance status of 0-1.
- No previous chemotherapy for advanced disease.
- Adequate functioning of the bone marrow, liver, and kidneys.
Exclusion 3
- Breastfeeding or pregnancy.
- An active second primary cancer with the exception of squamous cell carcinoma of the skin or an in situ cancer.
- Severe or uncompensated concomitant medical conditions.
Where
1 site, 1 recruiting
Allan Balir Cancer Center
Regina, Saskatchewan, Canada
Contact
-
Shahid Ahmed, MD, PhD
3066552710 shahid.ahmed@saskcancer.ca
-
Michael Moser
(306) 966-8641 michael.moser@usask.ca
Potential match only. Final eligibility is determined by the study team.